Namwiwat Medical (NAM) fair value: what the stock is really worth
We calculate from audited financials what Namwiwat Medical is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.
Compare price with fair valuebelow fair value = cheap, above = expensive
Check the quality50 and up solid, 75 and up strong
Watch it or check another stockalert when fair value or trend changes
Healthcare · TH · Market cap 2.3B THB (≈ $69.4M)
At a glance
NMNamwiwat MedicalNAM · BK
Price3.26 THB
Fair Value3.19 THB
Upside−2.2%
Quality48/100
Below-average quality, currently priced close to our fair value of 3.19 THB.
As of Aug 19, 2026, the fair value of Namwiwat Medical is 3.19 THB per share against a price of 3.26 THB, so the fair value sits 2% below the price. A model estimate from reported figures, not an analyst target.
!Expensive Growth (revenue 3y +19.4 %/yr)
!Thin margins · 4.0% net margin
!Low debt · negative free cash flow
·3.99% dividend yield
✓Ranks above peers (9/13)
!Narrow moat 38/100
!Evidence only low, so the estimate is less certain
!Weak on past: 13 out of 100
Evidence: LowRange 2.39 THB to 3.99 THB
Fair value as of: Aug 19, 2026
From 15 valuation models · updated 21 days ago
Share price −3.0% over the past month.
This is the short version. In the app for Namwiwat Medical:
Watch Namwiwat Medical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceable See the method →
What matters now
The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (3 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
34‑month range 3.26 THB – 6.68 THB · fair‑value band 2.39 THB – 3.99 THB · the 3.26 THB price screens above the 3.19 THB fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 19, 2026.
Namwiwat Medical (NAM) currently trades at 3.26 THB, while our model-based Fair Value estimate is 3.19 THB, implying the stock looks roughly 2.2% fairly valued today. The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of 5.35 THB per share, and 6 of the 15 models we run sit above the 3.26 THB price. Bear case: the Asset-Based group reads lowest at 1.91 THB, and 9 of the 15 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Namwiwat Medical generated revenue of 1.7B THB at a net margin of 4.0%. Revenue declined 29.9% year over year. It earns a return on equity of 3.4%. Net debt stands at 190M THB. Fundamentals as of Aug 19, 2026
Scenario range: 2.39 THB (bear) to 3.99 THB (bull), the price of 3.26 THB sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 23% below its 52-week high and 3% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −31% fair-value upside, at −2%, NAM screens cheaper than that median.
Fair Value models
Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →
ModelBear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence
Highest evidence
Residual Income best evidence2.16 THB2.17 THB2.05 THB73
EPV2.47 THB2.72 THB2.94 THB71
Owner Earnings3.00 THB5.35 THB9.93 THB70
All 15 models by family
DCF Models
Owner Earnings3.00 THB5.35 THB9.93 THB70
Earnings-Based
Graham-Dodd0.9900 THB6.37 THB8.91 THB60
Lynch FV1.85 THB2.64 THB3.43 THB58
PEG = 1.01.85 THB2.64 THB3.43 THB55
EPV2.47 THB2.72 THB2.94 THB71
Multiples
P/E Multiple2.39 THB3.19 THB3.99 THB63
P/S Multiple1.85 THB2.47 THB3.08 THB58
P/B Multiple1.85 THB2.47 THB3.08 THB55
EV/EBIT3.71 THB4.66 THB5.60 THB66
EV/EBITDA4.28 THB5.42 THB6.56 THB67
EV/Revenue2.90 THB3.77 THB4.63 THB54
Asset-Based
NCAV (Graham)1.43 THB1.91 THB2.86 THB54
Economic Profit
Residual Income best evidence2.16 THB2.17 THB2.05 THB73
ROIC Compounder2.47 THB2.72 THB3.07 THB69
Growth Earnings
Growth-Adj P/E2.66 THB3.80 THB4.94 THB65
Widest divergence: DCF Models (5.35 THB) versus Asset-Based (1.91 THB). Highest evidence: Residual Income (73).
Notify me when NAM reaches fair value
Put NAM on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
P/E ratio32.6
P/S ratio1.77P/E × margin
EPS (TTM)0.1000 THBprice ÷ EPS = P/E 32.6
Dividend yield4.0%payout 130%
Net margin5.4%FY2026
Return on equity3.4%TTM
More key figures
Profitability
Return on assets (EBIT)11.7%avg 5y
Operating margin5.1%TTM
Growth
Revenue (TTM)1.7B THBTTM
Revenue growth (YoY)−29.9%3y avg +19.4%
EPS growth (YoY)−83.5%
Balance sheet & cash flow
Free cash flow−30.8M THBFY2026
Net debt190M THBFY2023
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Overall quality48/100
Of which business quality 48
· Market factors (momentum, volatility) 41
Profitability34
Margins and returns on capital today
Quality Growth54
Are margins and returns improving?
Cashflow8
Earnings quality: real cash, not paper profit
Fin. Strength86
Balance sheet, leverage, solvency risk
Investment33
Disciplined investing over empire-building
Low Volatility94
Calm price path (market factor)
Momentum25
Price trend over the last 3–12 months (market factor)
52W Momentum10
Distance to the 52-week high (market factor)
Net Issuance82
Buybacks instead of dilution
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Namwiwat Medical Corporation Public Company Limited manufactures and distributes medical equipment in Thailand. The company offers steam and low temperature sterilizers, instrument washer disinfectors, ultrasonic cleaning systems, and drying cabinets, as well as waste sterilizers.
Full company description
Namwiwat Medical Corporation Public Company Limited manufactures and distributes medical equipment in Thailand. The company offers steam and low temperature sterilizers, instrument washer disinfectors, ultrasonic cleaning systems, and drying cabinets, as well as waste sterilizers. It also provides NAMTrack, a central sterile supply department software management product, as well as Air Track. In addition, the company offers air and surface disinfection equipment and air purifiers. Further, it provides medical supplies, disinfection services, medical equipment maintenance services, infectious waste services, and other medical services. The company was founded in 1970 and is based in Samut Prakan, Thailand.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Namwiwat Medical reported revenue of 1.9B THB in FY2026 versus 992M THB in FY2022, a compound +17.2%/yr. Reported net income was 102M THB in FY2026, compounding −12.7%/yr from FY2022.
Growth Quality 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Latest Revenue (FY 2026)
1.9B THB
Latest YoY
+67.8%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+19.4%
Value creation/yr (5Y, in THB) ⓘEarnings growth per share (CAGR 5 years, EBIT basis) plus dividend yield: value created per share and year. Measured in THB: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−3.5%
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share−7.5%
Dividend yield4.0%
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.23.2% (2022) → 8.3% (2026) · falling
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
This stockSector peers
VALUE31· sector 0
FUTURE0· sector 32
PAST13· sector 3
HEALTH98· sector 97
DIVIDEND80· sector 35
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
Is Namwiwat Medical (NAM) overvalued or undervalued?
As of Aug 19, 2026, our model estimates a fair value of 3.19 THB versus a price of 3.26 THB, about −2% upside (fairly valued).
What is the fair value of NAM?
Our model-based fair value for Namwiwat Medical is 3.19 THB (as of Aug 19, 2026), built from audited fundamentals. The current price: 3.26 THB.
What is the quality score of NAM?
Namwiwat Medical has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Namwiwat Medical (NAM)?
Our model-based price target is the fair value of 3.19 THB (as of Aug 19, 2026) from 15 valuation models. Cautious scenario 2.39 THB, optimistic scenario 3.99 THB. It is a calculation from audited fundamentals, not an analyst target.
What is the Namwiwat Medical stock forecast for 2026?
Our models put fair value at 3.19 THB, about −2% upside versus a price of 3.26 THB (fairly valued). Cautious scenario 2.39 THB, optimistic scenario 3.99 THB. The calculation is refreshed regularly with new filings.
What is the revenue of Namwiwat Medical (NAM)?
Namwiwat Medical reported trailing-twelve-month revenue of about 1.7B THB (latest available figure, as of Aug 19, 2026).
What is the net profit margin of NAM?
The net profit margin of Namwiwat Medical is about 4.0%, meaning it keeps roughly 4.0% of revenue as net income. Based on the latest reported figures.
Does Namwiwat Medical pay a dividend?
Namwiwat Medical currently shows a dividend yield of about 3.99% relative to its recent price (as of Aug 19, 2026).
What is the intrinsic value of Namwiwat Medical (NAM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Namwiwat Medical it is 3.19 THB per share (as of Aug 19, 2026), against a price of 3.26 THB. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Namwiwat Medical stock overvalued or undervalued in 2026?
As of Aug 19, 2026, NAM trades above its calculated fair value: price 3.26 THB, fair value 3.19 THB, a gap of about −2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NAM?
No. The price is what the market pays today (3.26 THB); the fair value is what the company's own numbers justify (3.19 THB). For Namwiwat Medical the two are 0.0700 THB per share apart. That gap is exactly why we show both numbers side by side.
How much is Namwiwat Medical worth?
The market values Namwiwat Medical at about 2.3B THB (market capitalisation, as of Aug 19, 2026). Per share that is 3.26 THB; our models calculate a fair value of 3.19 THB per share.
What do the bullish and bearish scenarios say about NAM?
Our models span a range for Namwiwat Medical: cautious scenario 2.39 THB, base 3.19 THB, optimistic 3.99 THB per share (as of Aug 19, 2026, price 3.26 THB). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of NAM?
Namwiwat Medical trades at a price-to-earnings ratio of 32.6 (as of Aug 19, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 3.19 THB is built from several models across several years. Other multiples: P/B 1.2, P/S 1.4, EV/EBITDA 12.1.
How solid is the balance sheet of Namwiwat Medical (NAM)?
Balance-sheet figures for Namwiwat Medical (as of Aug 19, 2026): return on equity 3.4%, debt of 0.04 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is NAM from its 52-week high?
Namwiwat Medical trades at 3.26 THB, about 23% below its 52-week high of 4.25 THB and 3% above the low of 3.17 THB (as of Aug 19, 2026). Distance from the high says nothing about value: that is what the fair value of 3.19 THB is for.
Which stocks are comparable to Namwiwat Medical?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Namwiwat Medical stock attractive at the current price?
The data as of Aug 19, 2026: price 3.26 THB, calculated fair value 3.19 THB (−2%), Quality Score 48/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NAM calculated?
We run Namwiwat Medical through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3.19 THB, with the spread shown as a cautious and an optimistic scenario.
Free · no account needed
Watch Namwiwat Medical in the live analysis
One click puts Namwiwat Medical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
